Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,449JPY
22 Nov 2019
Change (% chg)

¥-18 (-0.40%)
Prev Close
¥4,467
Open
¥4,409
Day's High
¥4,461
Day's Low
¥4,366
Volume
4,895,900
Avg. Vol
5,150,671
52-wk High
¥4,822
52-wk Low
¥3,401

Latest Key Developments (Source: Significant Developments)

Takeda Canada Says TAKHZYRO Gets Positive Recommendation From CADTH's CDEC For Routine Prevention Of HAE Attacks
1:15am IST 

Nov 22 (Reuters) - Takeda Canada::TAKEDA CANADA - TAKHZYRO GETS POSITIVE RECOMMENDATION FROM CADTH'S CANADIAN DRUG EXPERT COMMITTEE FOR ROUTINE PREVENTION OF HEREDITARY ANGIOEDEMA ATTACKS.  Full Article

Finch Therapeutics & Takeda Expand Collaboration To Develop Microbiome Therapeutics
Wednesday, 13 Nov 2019 

Nov 13 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::FINCH THERAPEUTICS & TAKEDA EXPAND COLLABORATION TO DEVELOP MICROBIOME THERAPEUTICS USING FINCH'S HUMAN-FIRST DISCOVERY PLATFORM.FINCH THERAPEUTICS - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED.FINCH THERAPEUTICS - UNDER TERMS, TAKEDA WILL RECEIVE EXCLUSIVE WORLDWIDE RIGHTS TO COMMERCIALIZE AN RSM PRODUCT DEVELOPED FOR CROHN'S DISEASE.  Full Article

Takeda And MD Anderson Announce Collaboration
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND MD ANDERSON ANNOUNCE COLLABORATION TO ACCELERATE THE DEVELOPMENT OF CLINICAL-STAGE, OFF-THE-SHELF CAR NK-CELL THERAPY PLATFORM.TAKEDA PHARMACEUTICAL CO LTD - ONGOING PHASE 1/2A STUDY OF CD19 CAR-NK WITH PIVOTAL STUDY EXPECTED TO ENROLL PATIENTS IN 2021.TAKEDA PHARMACEUTICAL CO LTD - MD ANDERSON WILL RECEIVE AN UPFRONT PAYMENT UNDER DEAL.TAKEDA PHARMACEUTICAL - MD ANDERSON ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONES FOR EACH TARGET AS WELL AS TIERED ROYALTIES UNDER DEAL.  Full Article

Takeda Continues Strategic Divestitures With Sale Of Select Otc And Non-Core Assets To STADA For $660 Million
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA CONTINUES STRATEGIC DIVESTITURES WITH SALE OF SELECT OTC AND NON-CORE ASSETS TO STADA FOR $660 MILLION USD.TAKEDA PHARMACEUTICAL - TAKEDA INTENDS TO USE PROCEEDS FROM THIS DIVESTITURE TO CONTINUE TO REDUCE ITS DEBT.TAKEDA PHARMACEUTICAL - AGREEMENT TO SELL PORTFOLIO OF ABOUT 20 SELECT OTC, PRESCRIPTION PHARMACEUTICAL ASSETS.TAKEDA PHARMACEUTICAL - CO , STADA TO ENTER INTO MANUFACTURING, SUPPLY AGREEMENTS; CO WILL CONTINUE TO MANUFACTURE, SUPPLY PRODUCTS TO STADA.  Full Article

Takeda Buys License For First-In-Class Celiac Disease Therapy From COUR Pharmaceuticals
Tuesday, 22 Oct 2019 

Oct 22 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ACQUIRES LICENSE FOR FIRST-IN-CLASS CELIAC DISEASE THERAPY FROM COUR PHARMACEUTICALS FOLLOWING POSITIVE PHASE 2A PROOF-OF-CONCEPT STUDY.TAKEDA PHARMACEUTICAL- TAKEDA ACQUIRES EXCLUSIVE GLOBAL LICENSE TO INVESTIGATIONAL MEDICINE CNP-101/TAK-101.TAKEDA-PRIMARY ENDPOINT OF TRIAL WAS ACHIEVED WITH MEAN CHANGE FROM BASELINE IN IFN-Γ ELISPOTSFUS OF 2.10 & 17.57 WITH TAK-101 & PLACEBO, RESPECTIVELY.TAKEDA PHARMACEUTICAL- INTENDS TO INITIATE A DOSE-RANGING STUDY TO EXPLORE THE POTENTIAL OF TAK-101 IN THE TREATMENT OF PATIENTS WITH CELIAC DISEASE .COUR ELIGIBLE TO RECEIVE UP TO $420 MLN IN FUTURE PAYMENTS, ROYALTIES ON SALES OF COMMERCIALIZED PRODUCTS RESULTING FROM LICENSE.  Full Article

PhRMA Names Eli Lilly Chairman And CEO, David Ricks, As Chairman-Elect
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Pharmaceutical Research and Manufacturers of America ::PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA SAYS DAVID RICKS, CHAIRMAN AND CEO OF ELI LILLY AND COMPANY, WAS NAMED CHAIRMAN-ELECT.PHRMA SAYS APPOINTED RAMONA SEQUEIRA, PRESIDENT OF TAKEDA PHARMACEUTICALS USA, TO THE ROLE OF BOARD TREASURER.  Full Article

Takeda Agrees To Divest Select OTC And Non-Core Assets To Acino For Over $200 Million USD
Tuesday, 15 Oct 2019 

Oct 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::AGREES TO DIVEST SELECT OTC AND NON-CORE ASSETS TO ACINO FOR OVER $200 MILLION USD.ENTERED DEAL TO DIVEST PORTFOLIO OF SELECT OTC & PRESCRIPTION PHARMACEUTICAL ASSETS IN NEMEA TO ACINO FOR IN EXCESS OF $200 MILLION.INTENDS TO USE DEAL PROCEEDS TO REDUCE DEBT, CONTINUE TO DELEVERAGE TOWARDS TARGET OF 2.0X NET DEBT/ADJUSTED EBITDA OVER NEXT 3 TO 5 YRS.UNDER TERMS OF AGREEMENT, ACINO WILL ACQUIRE RIGHTS, TITLE, INTEREST TO PRODUCTS IN PORTFOLIO EXCLUSIVE TO NEMEA COUNTRIES.HAS AGREED TO SELL PORTFOLIO OF ABOUT 30 SELECT PRESCRIPTION PHARMACEUTICAL AND OTC PRODUCTS SOLD IN NEMEA REGION TO ACINO.IT IS ANTICIPATED THAT PRIMARILY SALES AND MARKETING PROFESSIONALS SUPPORTING PORTFOLIO WILL TRANSITION TO ACINO AT CLOSING OF TRANSACTION.PARTIES WILL ENTER MULTI-YEAR MANUFACTURING AND SUPPLY AGREEMENT, IN WHICH TAKEDA WILL CONTINUE TO MANUFACTURE PRODUCTS ON BEHALF OF ACINO.TRANSACTION IS EXPECTED TO CLOSE IN Q4 FY19.  Full Article

ImaginAb Signs Multi-Party Collaboration Agreement With 3 Global Pharmaceutical Cos
Monday, 14 Oct 2019 

Oct 14 (Reuters) - ImaginAb::IMAGINAB SIGNS MULTI-PARTY COLLABORATION AGREEMENT WITH 3 GLOBAL PHARMACEUTICAL COS TO HELP FURTHER DEVELOP CO'S CD8 IMMUNOPET TECHNOLOGY.ANNOUNCED SIGNING OF MULTI-PARTY AGREEMENT WITH ASTRAZENECA, PFIZER, TAKEDA PHARMACEUTICAL.COLLABORATORS TO HELP GUIDE IMAGINAB-SPONSORED CLINICAL TRIAL AIMING TO EVALUATE UTILITY, VALUE OF CD8 IMMUNOPET IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT.COLLABORATORS WILL GAIN EARLY ACCESS TO CLINICAL & IMAGING DATA & COLLECTIVELY CONTRIBUTE TO POST-TRIAL DATA ANALYSIS.  Full Article

Cerveau Technologies Inc Signs Research Agreement With Takeda To Provide Novel Tau Imaging Agent
Friday, 27 Sep 2019 

Sept 27 (Reuters) - Cerveau Technologies Inc::CERVEAU TECHNOLOGIES INC. SIGNS RESEARCH AGREEMENT WITH TAKEDA TO PROVIDE NOVEL TAU IMAGING AGENT.CERVEAU TECHNOLOGIES -WITH COLLABORATION, TAKEDA TO USE CO'S INVESTIGATIONAL IMAGING AGENT IN PET SCANS TO ASSESS STATUS, PROGRESSION OF NFTS IN BRAIN.  Full Article

Takeda Issues U.S. Recall Of NATPARA For Injection Due To The Potential For Rubber Particulate
Friday, 6 Sep 2019 

Sept 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ISSUES US RECALL OF NATPARA® (PARATHYROID HORMONE) FOR INJECTION DUE TO THE POTENTIAL FOR RUBBER PARTICULATE.TAKEDA - RECALL IS EFFECTIVE IMMEDIATELY DUE TO POTENTIAL ISSUE RELATED TO RUBBER PARTICULATES ORIGINATING FROM RUBBER SEPTUM OF NATPARA CARTRIDGE.TAKEDA PHARMACEUTICAL CO LTD - RECALL IS BEING CONDUCTED AFTER DISCUSSIONS WITH FDA.  Full Article

Photo

Stada buys Takeda drug bundle to boost Russia business

Germany's Stada on Tuesday agreed to purchase over-the-counter and prescription drugs units from Japan's largest drugmaker Takeda for $660 million, part of two deals that boost its Russian and Eastern European footprint.